Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on Gilead (GILD) to $135 from $129 and keeps an Overweight rating on the shares. Third quarter results are expected to have limited market impact as attention remains on upcoming White House policy developments, key peripheral events, and 2026 outlook commentary, the analyst tells investors in a research note. Any positive reaction to policy clarity is likely to be more muted than in prior quarters, resulting in fewer portfolio positioning changes, the firm says.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $135 from $125 at Citi
- Gilead Sciences: Strategic Positioning and Extended Patent Protection Justify Buy Rating
- Wells says Biktarvy patent settlement ‘big deal’ for Gilead at, $6-$12 upside
- Gilead Sciences Settles Patent Litigation on Biktarvy
- Gilead settles patent litigations with Biktarvy ANDA filerers
